Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderActive Not Recruiting
NCT03317158Phase 1, Phase 2Updated Jul 15, 2026
Sponsor: Noah Hahn, M.D.
Urothelial Carcinoma · Bladder Cancer
United States
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With AsthmaCompleted
NCT07433569Phase 1Updated Jul 15, 2026
Sponsor: AstraZeneca
Asthma
United States
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular CarcinomaActive Not Recruiting
NCT03778957Phase 3Updated Jul 15, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma
United States, Australia, Brazil, Canada, China +13 more
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBERecruiting
NCT07245407N/AUpdated Jul 14, 2026
Sponsor: AstraZeneca
Non-cystic Fibrosis Bronchiectasis
China
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCLActive Not Recruiting
NCT02717624Phase 1Updated Jul 14, 2026
Sponsor: Acerta Pharma BV
Mantle Cell Lymphoma (MCL)
United States, Italy, Poland
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCActive Not Recruiting
NCT04995523Phase 1, Phase 2Updated Jul 14, 2026
Sponsor: AstraZeneca
Non-Small-Cell Lung Carcinoma
United States, Australia, Belgium, Brazil, China +11 more
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast CancerActive Not Recruiting
NCT02032823Phase 3Updated Jul 14, 2026
Sponsor: AstraZeneca
Breast Cancer
United States, Argentina, Australia, Austria, Belgium +19 more
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG StudiesRecruiting
NCT03847649Phase 2Updated Jul 14, 2026
Sponsor: Canadian Cancer Trials Group
Cancer
Canada
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaRecruiting
NCT06921785Phase 3Updated Jul 14, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma
United States, Australia, Brazil, Canada, China +15 more
Optimizing Care For Management Of Hard To Control Hypertension In Low-Income Patients Across Family Health Centers In New York CityNot Yet Recruiting
NCT07703423NAUpdated Jul 14, 2026
Sponsor: NYU Langone Health
Hypertension
United States
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung CancerCompleted
NCT03519971Phase 3Updated Jul 14, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
Brazil, Czechia, Hungary, India, Japan +9 more
Savolitinib vs. Sunitinib in MET-driven PRCC.Active Not Recruiting
NCT03091192Phase 3Updated Jul 14, 2026
Sponsor: AstraZeneca
Carcinoma · Carcinoma, Renal Cell · Kidney Neoplasms · Urologic Neoplasms
United States, Brazil, France, Italy, Russia +2 more
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CMActive Not Recruiting
NCT07608354Phase 2Updated Jul 14, 2026
Sponsor: AstraZeneca
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
United States, Canada, China, France, Germany +5 more
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial CancerActive Not Recruiting
NCT02516241Phase 3Updated Jul 14, 2026
Sponsor: AstraZeneca
Urothelial Cancer
United States, Australia, Austria, Belgium, Brazil +19 more
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.Active Not Recruiting
NCT02734004Phase 1, Phase 2Updated Jul 14, 2026
Sponsor: AstraZeneca
Ovarian · Breast · SCLC · Gastric Cancers
United States, France, Israel, Netherlands, South Korea +2 more
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusRecruiting
NCT07662213Phase 3Updated Jul 14, 2026
Sponsor: AstraZeneca
Type 2 Diabetes Mellitus
United States, Argentina, Australia, Brazil, Bulgaria +10 more
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated EosinophilsCompleted
NCT06897748Phase 2Updated Jul 14, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Russia
A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)Recruiting
NCT07613424NAUpdated Jul 14, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
China
SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBCNot Yet Recruiting
NCT07701070N/AUpdated Jul 14, 2026
Sponsor: AstraZeneca
Advanced Breast Cancer
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active Not Recruiting
NCT04964934Phase 3Updated Jul 14, 2026
Sponsor: AstraZeneca
ER-Positive HER2-Negative Breast Cancer
United States, Australia, Austria, Belgium, Bulgaria +18 more
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive Not Recruiting
NCT05450692Phase 3Updated Jul 13, 2026
Sponsor: AstraZeneca
Advanced or Metastatic Non-Small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +18 more
CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLCRecruiting
NCT07413757N/AUpdated Jul 13, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
China
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive Not Recruiting
NCT05301842Phase 3Updated Jul 13, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma
United States, Belgium, Brazil, Canada, China +17 more
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)Recruiting
NCT07073547Phase 1Updated Jul 13, 2026
Sponsor: AstraZeneca
Multiple Myeloma
United States
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid TumorsRecruiting
NCT06130553Phase 1, Phase 2Updated Jul 13, 2026
Sponsor: AstraZeneca
Advanced Solid Tumors That Are MTAP Deficient
United States, Australia, China, France, Japan +3 more

Previous page Next page